Alexander Wilson - 31 Aug 2024 Form 4 Insider Report for AEON Biopharma, Inc. (AEON)

Role
EXEC VP, CLO & CORP SECRETARY
Signature
/s/ Alexander Wilson
Issuer symbol
AEON
Transactions as of
31 Aug 2024
Transactions value $
$0
Form type
4
Date filed
04 Sep 2024, 21:58
Previous filing
21 Mar 2024
Next filing
23 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AEON Class A Common Stock Award $0 +180K +221.19% $0.00 262K 31 Aug 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AEON Stock Option Award $0 +481K $0.00 481K 31 Aug 2024 Class A Common Stock 481K $0.83 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an award of restricted stock units granted on August 31, 2024 (the "Grant Date"), which vests in full on the second anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date.
F2 Includes an award of restricted stock units ("RSUs") in the amount of 81,428 previously granted on April 26, 2023, which were previously reported on July 24, 2023 as derivative securities in Table II due to a clerical error, and which are now being reported as common stock in Table I. The vesting terms for the RSUs have not changed from what was previously reported on July 24, 2023.
F3 Represents an award of stock options granted on August 31, 2024 (the "Grant Date"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date.